ClinicalTrials.gg
Active, not recruitingNCT07211776Updated Sep 9, 2026

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

A Phase 3 interventional study of ZL-1109 (VRDN-003) and Placebo in Thyroid Eye Disease (TED), sponsored by Zai Lab (Shanghai) Co., Ltd.. Active, not recruiting at 26 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Enrollment
12th of 45
108 · median 64
Started
2025
with 10 others
Phase 3
13 of 55
4 open now
Primary completion
2027-03
later than 9 of 27 live
Registered
42nd of 55
by date

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 12th largest by enrollment of the 45 interventional ones that give a count, is one of 11 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 9 of the 27 other live ones, and was the 42nd registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)

Read the detailed description

This is a multicenter, Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of ZL-1109 in participants with active TED. The study will comprise a screening period of up to 28 days, a double-blinded randomized placebo-controlled period of 24 weeks and an extension period. For responders and non-responders who do not want to receive open-label treatment, the study period is 52 weeks from the first dose. For non-responders who consent to and are considered eligible to receive open-label treatment, the study period is 70 weeks from the first dose.

03

Conditions studied

  • Thyroid Eye Disease (TED)

Browse trials for

Keywords

  • Thyroid Eye Disease (TED)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Have moderate to severe TED
  2. Must meet the clinical diagnosis criteria of active TED
  3. Must agree to use highly effective as specified in the protocol
  4. Female TED participants must have a negative serum pregnancy test at screening

Key Exclusion Criteria:

  1. Have received prior treatment with another anti-IGF-1R mAb or anti-thyroid stimulating hormone receptor (TSHR) mAb.
  2. Have received systemic or steroid eye drops for any condition, or other drugs for any condition, including TED, or radioactive iodine (RAI) treatment within a certain period prior to first dose.
  3. Have corneal decompensation in the study eye unresponsive to medical management.
  4. Have a pre-existing ophthalmic in the study eye which in the opinion of the Investigator, would confound interpretation of the study results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Randomized controlled period: ZL-1109 every 4 weeks

    Participants will receive ZL-1109 per protocol defined dosing regimen.

    Drug: ZL-1109 (VRDN-003)

  • Experimental
    Randomized controlled period: ZL-1109 every 8 weeks

    Participants will receive ZL-1109 and placebo per protocol defined dosing regimen.

    Drug: ZL-1109 (VRDN-003) · Drug: Placebo

  • Placebo comparator
    Randomized controlled period: Placebo every 4 weeks

    Participants will receive placebo per protocol defined dosing regimen.

    Drug: Placebo

  • Other
    OLE treatment period: ZL-1109 every 4 weeks

    Participants who not responded would receive ZL-1109 per protocol defined dosing regimen.

    Drug: ZL-1109 (VRDN-003)

Interventions

  • ZL-1109 subcutaneous injection

  • DrugPlacebo

    Matching placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Proptosis Responder Rate in the study eye

    Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \[without a corresponding increase of ≥2 mm in the fellow eye\]

    Time frame: At Week 24

Secondary outcomes

  1. Change from baseline in proptosis in the study eye

    Change from baseline in proptosis in the study eye

    Time frame: At Week 24

  2. Overall Responder Rate in the study eye

    Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \[without a corresponding increase of ≥2 mm in the fellow eye\]) AND ≥ 2 points reduction in CAS from baseline in the study eye \[without a corresponding increase of ≥2 points in the fellow eye\]

    Time frame: At Week 24

  3. Change from baseline in Clinical Activity Score (CAS) in the study eye

    Change from baseline in CAS in the study eye \[range, 0 to 7, with higher scores indicating greater level of inflammation\]

    Time frame: At Week 24

  4. Proportion of participants with a Clinical Activity Score (CAS) of 0 or 1 in the study eye

    Proportion of participants with a CAS of 0 or 1 in the study eye

    Time frame: At Week 24

  5. Diplopia Responder Rate for participants with baseline Diplopia Score greater than 0

    Proportion of participants with a reduction in Diplopia Score of ≥1 from baseline (for participants with baseline Diplopia Score greater than 0)

    Time frame: At Week 24

  6. Diplopia Resolution Rate for participants with baseline Diplopia Score greater than 0

    Proportion of participants with a reduction in Diplopia Score to 0 from baseline (for participants with baseline Diplopia Score greater than 0)

    Time frame: At Week 24

  7. Clinical Activity Responder Rate in the study eye

    Clinical Activity Responder Rate in the study eye (i.e., ≥ 2 points reduction in CAS from baseline in the study eye \[without a corresponding increase of ≥2 points in the fellow eye\])

    Time frame: At Week 24

07

Study locations

26 sites
  • Site01006
    Beijing, China
  • Site01009
    Beijing, China
  • Site01010
    Beijing, China
  • Site01029
    Bengbu, China
  • Site01020
    Changsha, China
  • Site01022
    Chengdu, China
  • Site01031
    Chongqing, China
  • Site01011
    Dalian, China
  • Site01008
    Foshan, China
  • Site01004
    Fuzhou, China
  • Site01007
    Guangzhou, China
  • Site01027
    Guiyang, China
  • Site01018
    Hangzhou, China
  • Site01002
    Hefei, China
  • Site01024
    Jinan, China
  • Site01005
    Luoyang, China
  • Site01017
    Nanchang, China
  • Site01001
    Shanghai, China
  • Site01012
    Shenyang, China
  • Site01023
    Taiyuan, China
  • Site01013
    Tianjin, China
  • Site01016
    Wuxi, China
  • Site01028
    Xi'an, China
  • Site01026
    Yangzhou, China
  • Site01019
    Zhengzhou, China
  • Site01030
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No — The study team does not plan to make individual participant data underlying the published results publicly available. This decision is based on two key considerations: (1) the absence of informed consent at the participant level for reuse of data beyond the pre-specified analyses outlined in the study protocol; (2) applicable privacy regulations in relevant jurisdictions which restrict the further dissemination of personally identifiable information. Aggregate-level data supporting the primary findings of the study will be made available through supplementary materials accompanying the publication, and may also be shared upon reasonable request to the corresponding author for purposes such as meta-analysis or regulatory review, provided that a formal data use agreement is executed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Mar 14, 2027
CompletionEst.
Jan 29, 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211776
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Dec 5, 2025
Primary completion
Mar 14, 2027 (estimated)
Completion
Jan 29, 2028 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elegrobart

Start the discussion